Skip to main content
OpenTrials
Completed

NCT Number: NCT02647905

Evaluation of the Accuracy of an Implanted Glucose Sensor

The purpose of this clinical investigation is to evaluate the accuracy of the Senseonics Continuous Glucose Monitoring System (Senseonics CGM System) measurements when compared with reference standard measurements The investigation will also evaluate safety of the Senseonics CGM System usage.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

John Muir Physician Network Clinical Research Center, Concord, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult subjects, age ≥18 years
  • Clinically confirmed diagnosis of diabetes mellitus for ≥1 year
  • Subject has signed an informed consent form and is willing to comply with protocol requirements

Exclusion criteria

  • History of severe hypoglycemia in the previous 6 months. Severe hypoglycemia is defined as hypoglycemia resulting in loss of consciousness or seizure
  • History of diabetic ketoacidosis requiring emergency room visit or hospitalization in the previous 6 months
  • Female subjects of childbearing capacity (defined as not surgically sterile or not menopausal for ≥ 1 year) who are lactating or pregnant, intending to become pregnant, or not practicing birth control during the course of the study.
  • A condition preventing or complicating the placement, operation, or removal of the Sensor or wearing of transmitter, including upper extremity deformities or skin condition.
  • Symptomatic coronary artery disease; unstable angina; myocardial infarction, transient ischemic attack or stroke in the past 6 months; uncontrolled hypertension (systolic>160 mm Hg or diastolic >100 mm Hg at time of screening); current congestive heart failure; history of cardiac arrhythmia (benign PACs and PVCs allowed). Subjects with asymptomatic coronary artery disease (e,g, CABG, stent placement or angioplasty) may participate if negative stress test within 1 year prior to screening and written clearance from Cardiologist documented.
  • Hematocrit <30% or >55%
  • History of hepatitis B, hepatitis C, or HIV
  • Any condition that in the investigator's opinion would make the subject unable to complete the study or would make it not in the subject's best interest to participate in the study.

Treatment and study plan

Continuous Glucose Monitoring System

Device

Accuracy and safety assessment of a continuous glucose monitoring device

Primary outcomes

  1. CGM Relative Difference to Laboratory Reference Reported as MARD

    Time frame: 90 days

    Mean absolute relative difference (MARD) for paired Sensor and reference measurements through 90 days post-insertion for reference glucose values from 40-400 mg/dL will be calculated for comparison.

Other outcomes

  1. CGM System Agreement With Reference Control

    Time frame: 90 days

    The percentage of system readings within ±15 mg/dL or 15% of YSI reference values (15/15%)

Sponsors and collaborators

Lead sponsor

Senseonics, Inc.

Industry

Registry information

Official study title

A Prospective, Multicenter Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor, PRECISE II

Acronym: PRECISEII

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Jan 6, 2016
Registry last updated
Jun 6, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.